Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets

Rapafusyn的RapaGlue™平台迅速发现了非降解分子胶，这是一种经过验证且备受追捧的方式，可解决具有挑战性或以前无法治愈的疾病目标

Financing led by 3E Bioventures Capital and Proxima Ventures Ltd. with participation from Lapam Capital

融资由3E Bioventures Capital和Proxima Ventures Ltd.牵头，Lapam Capital参与

Founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular glue field

由约翰·霍普金斯大学医学院刘军教授创立，他是分子胶领域的先驱

Baltimore, MD– June 20, 2024

马里兰州巴尔的摩——2024年6月20日

Rapafusyn Pharmaceuticals, a leader in the discovery and development of therapeutic drugs based on non-degrading molecular glues, today announced the initial closings of an extension of its Series A financing, bringing the total round to $28 Million.  The financing was led by 3E Bioventures Capital and Proxima Ventures Ltd.

Rapafusyn Pharmaceuticals是发现和开发基于非降解分子胶的治疗药物的领导者，今天宣布首次关闭其a系列融资的延期，总金额达到2800万美元。融资由3E Bioventures Capital和Proxima Ventures Ltd领导。

with participation from Lapam Capital..

由Lapam Capital参与。。

The financing will propel the progress of Rapafusyn's innovative and diverse pipeline of macrocyclic peptide-based non-degrading molecular glues and further enhance its internal capabilities.  Rapafusyn’s industry-leading libraries of RapaGlues™ can swiftly produce novel chemical entities for targets that are traditionally challenging or currently undruggable by other modalities.

该融资将推动Rapafusyn创新和多样化的基于大环肽的非降解分子胶管道的进展，并进一步增强其内部能力。Rapafusyn业界领先的RapaGlues™文库可以快速为传统上具有挑战性或目前无法通过其他方式治疗的目标生产新型化学实体。

This innovative breakthrough offers a promising solution for numerous difficult-to-drug targets, paving the way for significant advancements in drug discovery and development to address high unmet medical needs of patients..

这一创新性突破为许多难以药物靶点提供了一个有前途的解决方案，为药物发现和开发的重大进步铺平了道路，以解决患者高度未满足的医疗需求。。

“Non-degrading molecular glues were previously found serendipitously.  The RapaGlue™ platform has the ability to create non-degrading molecular glues by design”, said Dr. Jun O. Liu, scientific founder of Rapafusyn and a pioneer whose ground-breaking discovery of the molecular glue mechanism for FK506 and cyclosporin A at Harvard University with Professor Stuart Schreiber and colleagues in 1991 formed the foundation of the field of non-degrading molecular glues. .

Rapafusyn的科学创始人Jun O.Liu博士说：“非降解分子胶以前是偶然发现的。RapaGlue™平台能够通过设计产生非降解分子胶”，他是一位先驱，1991年与斯图尔特·施雷伯教授及其同事在哈佛大学开创性地发现了FK506和环孢菌素a的分子胶机制，奠定了非降解分子胶领域的基础。。

'Our RapaGlue™ platform is primed to bring groundbreaking therapies to patients. This innovative non-degrading molecular glue modality integrates the benefits of molecular glues with cyclic peptides, creating cell-permeable drug candidates.  Our robust platform allows us to tackle disease targets where other modalities have struggled.'   Dr.

“我们的RapaGlue™平台已准备好为患者带来开创性的治疗方法。这种创新的非降解分子胶模式将分子胶与环肽的优点结合在一起，产生了可渗透细胞的候选药物。我们强大的平台使我们能够应对其他模式难以应对的疾病目标。”博士。

Sean Hu, CEO of Rapafusyn, commented.  “We are very pleased to have such distinguished investors participate in this round of financing.”.

Rapafusyn首席执行官肖恩·胡（SeanHu）评论道。“我们很高兴有如此杰出的投资者参与这轮融资。”。

“Rapafusyn offers a new class of macrocyclic molecules that function as non-degrading molecular glues. It can target a broad range of membrane or intracellular targets, including those traditionally difficult-to-drug, such as PPIs (protein-protein interaction targets), transcriptions factors, SLCs/transporters, ion channels and others”, said Dr.

“Rapafusyn提供了一类新的大环分子，可作为非降解分子胶发挥作用。它可以靶向广泛的膜或细胞内靶标，包括传统上难以药物治疗的靶标，如PPI（蛋白质-蛋白质相互作用靶标），转录因子，SLC/转运蛋白，离子通道等”，Dr。

Karen Liu, a Founding Partner at 3E Bioventures.  “I am excited about the platform, because for the first time in drug discovery, we have a systematic and efficient way to screen for small molecule modulators beyond the traditional Lipinski rules and protein degraders popular in recent years.”.

Karen Liu是3E Bioventures的创始合伙人。“我对这个平台感到兴奋，因为在药物发现方面，我们首次有了一种系统而有效的方法来筛选小分子调节剂，超越了传统的Lipinski规则和近年来流行的蛋白质降解剂。”。

Haolin Sung, Partner at Proxima Ventures commented, “We are very attracted by and delighted to invest in Rapafusyn’s non-degrading molecular glue platform. It is well differentiated and, in many ways, superior to other drug modalities in addressing challenging or undruggable disease targets. We are also impressed by the caliber of the Rapafusyn operating and advisory teams and are confident in the future success of the company.”.

Proxima Ventures合伙人Haolin Sung评论道：“我们非常喜欢并很高兴投资Rapafusyn的非降解分子胶平台。它差异化程度很高，在许多方面优于其他药物模式，可以解决具有挑战性或不可治疗的疾病目标。我们也对Rapafusyn运营和咨询团队的才干留下了深刻印象，并对公司未来的成功充满信心。”。

Mr. Zhihua Yu, Founding Managing Parter of Lapam Capital added, “By applying an innovative and well validated approach to effectively drug a broad spectrum of challenging or undruggable disease targets, Rapafusyn has the potential to address a major gap and unmet need in the pharma industry.  We believe in Rapafusyn’s potential to discover transformational medicines to benefit patients globally.”.

Lapam Capital创始人兼管理合伙人余志华先生补充道：“通过应用创新且经过充分验证的方法有效治疗广泛的具有挑战性或不可治疗的疾病靶标，Rapafusyn有潜力解决制药行业的主要差距和未满足的需求。我们相信Rapafusyn有潜力发现转化药物，使全球患者受益。”。

About 3E Bioventures

关于3E Bioventures

3E Bioventures Capital is a life science focused VC fund, actively investing in global leading health innovators, investing in Biotech (new drugs, new modalities, and drug discovery platforms) and in TechBio, the intersection of biology and technology that can potentially disrupt old paradigms.  3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs..

3E Bioventures Capital是一家专注于生命科学的风险投资基金，积极投资于全球领先的健康创新者，投资于生物技术（新药，新模式和药物发现平台）和TechBio，这是生物学和技术的交叉点，可能会破坏旧的范式。3E Bioventures通过与公司和研究机构密切合作，开发具有强烈未满足医疗需求的药物或产品，秉承科学驱动、企业家友好的投资理念。。

About Proxima Ventures

关于Proxima Ventures

Proxima Ventures is a respected VC fund focused on investing in innovative and disruptive medical and bio- technologies, dedicated to serving outstanding and innovative companies with tremendous potential for growth. Proxima Ventures is run by a highly experienced team with proven track record in the life science industries.

Proxima Ventures是一家备受尊敬的风险投资基金，专注于投资创新和颠覆性的医疗和生物技术，致力于为具有巨大增长潜力的优秀创新公司提供服务。Proxima Ventures由一支经验丰富的团队运营，在生命科学行业拥有良好的业绩记录。

The team has broad global knowledge, in-depth experience, and an extensive industry network. Currently, Proxima has multiple Chinese Yuan (RMB) and USD funds under its management, investing in angel to growth stage companies. Proxima Ventures has established a leading medical entrepreneurship ecosystem, helped its portfolio companies connect with high-quality clinical and industrial resources, and achieved remarkable results..

。Proxima Ventures建立了领先的医疗创业生态系统，帮助其投资组合公司连接了高质量的临床和行业资源，并取得了显著成效。。

About Lapam Capital

关于Lapam Capital

Headquartered in Beijing, Lapam Capital is a leading healthcare venture capital firm in China. Lapam is currently managing five RMB (Chinese Yuan) funds and one USD fund, with more than 10 billion RMB under management. Lapam Capital focuses on investments in early to mid- stage fast-growing companies that have innovative pharmaceuticals and medical devices.

Lapam Capital总部位于北京，是中国领先的医疗风险投资公司。Lapam目前管理五只人民币（人民币）基金和一只美元基金，管理金额超过100亿元人民币。Lapam Capital专注于对拥有创新药品和医疗设备的早期至中期快速增长公司的投资。

Its investment portfolio currently consists of 120+ projects, of which innovative drug therapeutics projects account for over 80%, including Betta Pharma, RemeGen Co. Ltd., Gyre Therapeutics, Asieris Pharmaceuticals, ImmuneOnco Biopharmaceuticals, Binhui Biotech, Biostar Pharmaceuticals, Eyebright Medical Technology Ltd., and many other companies with great potential.

其投资组合目前由120多个项目组成，其中创新药物治疗项目占80%以上，包括Betta Pharma，RemeGen Co.Ltd.，Gyre therapeutics，Asieris Pharmaceuticals，ImmuneOnco Biopharmaceuticals，Binhui Biotech，Biostar Pharmaceuticals，Eyebright Medical Technology Ltd。和许多其他具有巨大潜力的公司。

Lapam Capital has a professional investment team with more than 20 years of international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added support for the invested companies..

Lapam Capital拥有一支拥有20多年国际国内生物制药行业研发和管理经验的专业投资团队，可为被投资公司提供全面的增值支持。。

About Rapafusyn Pharmaceuticals

关于Rapafusyn Pharmaceuticals

Rapafusyn emerged from the laboratory of Dr. Jun O. Liu’s, Professor of Pharmacology and Molecular Sciences at Johns Hopkins University, with a mission to develop transformational medicines to address high unmet medical needs and enhance patient care.  The platform leverages non-degrading macrocyclic molecular glues (RapaGluesTM) to address challenging therapeutic targets.  Rapafusyn has constructed both DNA-encoded libraries (DELs) and arrayed libraries of RapaGluesTM that form neo-PPIs to inhibit a protein from its native activity.

Rapafusyn来自约翰·霍普金斯大学药理学和分子科学教授Jun O.Liu博士的实验室，其使命是开发转化药物，以满足高度未满足的医疗需求并加强患者护理。该平台利用非降解大环分子胶（RapaGluesTM）来解决具有挑战性的治疗目标。Rapafusyn已经构建了DNA编码文库（DEL）和RapaGluesTM的阵列文库，它们形成新PPI以抑制蛋白质的天然活性。

These compounds are rationally designed and engineered to bind FKBP and form a ternary complex with the disease target protein, offering a promising avenue for modulating intricate protein-protein interactions.  RapaGluesTM have proven effective in producing innovative chemical starting points for challenging drug targets.  The modular architecture enables SAR and subsequent optimization for potency, selectivity, and physicochemical properties to accelerate drug discovery and development.

这些化合物经过合理设计和工程改造，可与FKBP结合，并与疾病靶蛋白形成三元复合物，为调节复杂的蛋白质-蛋白质相互作用提供了有希望的途径。事实证明，RapaGluesTM在为具有挑战性的药物靶标产生创新的化学起点方面是有效的。模块化体系结构使SAR和随后的效力，选择性和理化性质优化成为可能，以加速药物的发现和开发。

RapaGluesTM frequently exhibit cell permeability directly from the starting point, enhancing their potential for therapeutic development..

RapaGluesTM经常从一开始就直接表现出细胞通透性，增强了其治疗发展的潜力。。

For more information, please visit rapafusyn.com or contact Heather Lavin: hlavin@rapafusyn.com

有关更多信息，请访问rapafusyn.com或联系Heather Lavin：hlavin@rapafusyn.com